Larske M Soepnel, Shane A Norris, Khuthala Mabetha, Molebogeng Motlhatlhedi, Nokuthula Nkosi, Stephen Lye, Catherine E Draper
A qualitative analysis of community health worker perspectives on the implementation of the preconception and pregnancy phases of the Bukhali randomised controlled trial
PLOS global public health
subcutaneous sc infliximab may provide multiple benefits intravenous iv formulations however studies efficacy safety inflammatory bowel disease ibd constrained small sizes limit interpretation outcomes especially subgroups potentially highrisk disease relapse conducted systematic review randomeffects metaanalysis january 2023 evaluate change clinical remission transitioning iv sc infliximab patients ibd clinical remission primary outcome measured using relative risk metaanalysis 15 studies patients established 3 months iv infliximab identified consisting 1371 patients 840 patientyears followup loss clinical remission ibd cohort overall crohns disease cd perianal cd p055 p011 912 months p050 6 months respectively neither prior iv dose 10mgkg 6weekly p048 ibd disease subtype associated increased clinical relapse rate 6 months p048 p045 uc vs cd respectively changing patients established iv infliximab sc formulation associated high ongoing clinical remission low adverse event rate furthermore signals adverse outcomes among different ibd disease subtypes escalated iv infliximab dosing schedules 10mgkg 6weekly data provide patients clinicians alike confidence sc infliximab use ibd